Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Shares Outstanding (2021 - 2025)

Krystal Biotech's Shares Outstanding history spans 5 years, with the latest figure at $29.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.38% year-over-year to $29.2 million; the TTM value through Dec 2025 reached $29.2 million, up 1.38%, while the annual FY2025 figure was $29.2 million, 1.38% up from the prior year.
  • Shares Outstanding for Q4 2025 was $29.2 million at Krystal Biotech, up from $29.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $29.2 million in Q4 2025 and bottomed at $22.2 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $28.1 million (2023), against an average of $26.8 million.
  • The largest annual shift saw Shares Outstanding increased 15.61% in 2022 before it increased 0.76% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $25.2 million in 2021, then rose by 2.21% to $25.8 million in 2022, then rose by 9.6% to $28.2 million in 2023, then increased by 1.97% to $28.8 million in 2024, then rose by 1.38% to $29.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Shares Outstanding are $29.2 million (Q4 2025), $29.0 million (Q3 2025), and $28.9 million (Q2 2025).